Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.

Emilie ChartonJean-Baptiste BachetPascal HammelJérôme DesraméBenoist ChibaudelRomain CohenPhilippe DebourdeauJérome DaubaThierry LecomteJean-François SeitzChristophe TournigandThomas AparicioVéronique Guerin-MeyerJulien TaiebJulien VoletChristophe LouvetAmélie AnotaFranck Bonnetain

Published in: Cancer medicine (2019)

The nab-paclitaxel plus simplified leucovorin and fluorouracil combination had no negative impact in exploratory HRQoL analyses.

Keyphrases

phase ii
clinical trial
open label
free survival
double blind
phase iii
placebo controlled
advanced non small cell lung cancer
study protocol
stem cells
randomized controlled trial
cell therapy